NCT06892275 The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
| NCT ID | NCT06892275 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Georgetown University |
| Condition | Breast Neoplasm Female |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-06-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.
Eligibility Criteria
Inclusion Criteria: * female * aged 18-74 years * self-identifying as Black and/or Latina * no personal history of breast cancer * English- or Spanish-speaking * having received a mammogram with normal results in the last 12 months * ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT) Exclusion Criteria: * aged \<18 or ≥75 * pregnancy
Contact & Investigator
Claire C. Conley, PhD
PRINCIPAL INVESTIGATOR
Georgetown University
Frequently Asked Questions
Who can join the NCT06892275 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 74 Years, studying Breast Neoplasm Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06892275 currently recruiting?
Yes, NCT06892275 is actively recruiting participants. Contact the research team at claire.conley@georgetown.edu for enrollment information.
Where is the NCT06892275 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT06892275 clinical trial?
NCT06892275 is sponsored by Georgetown University. The principal investigator is Claire C. Conley, PhD at Georgetown University. The trial plans to enroll 80 participants.